

# **Inorganic Nanoparticles for medical applications**



H. Hofman Powder Technology Laboratory


# Outline

2

- Overview
- Why inorganic Nanoparticles for medical applications?
  - Needs from the medical side
  - Potential from the material side
- Examples:
  - Silica
  - QD
  - SPION
- Interaction of nanoparticles with tissue, cells, proteins

# The medicinal chemist looks at the vast landscape of nanomaterials.

3




# Preliminary statements

4

- The landscape of nanomaterials for medicines is rich with options, and innovative solutions will likely be found in the wise combination of different components.
- The researchers who venture into this field should reach out to and partner with physicists, biologists, and clinicians to find creative solutions to these complex, multidisciplinary problems.

# Interactions in Nanoscience and Nanotechnology



# Outline

6

- Overview
- **Why inorganic Nanoparticles for medical applications?**
  - **Needs from the medical side**
  - **Potential from the material side**
- Examples:
  - Silica
  - QD
  - SPION
- Interaction of nanoparticles with tissue, cells, proteins

# Bioanalysis and Diagnostics :

7

- New platforms include the use of nanoparticles (dots, bars, rods) as labels for biomolecules for separation and screening, as well as nanopore and nanoscale fluidic assay systems and self-assembling arrays of nanoparticles.
- For patient monitoring and diagnosis it needs more efficient and selective Nanoparticles for diagnostics at clinical level (MRI contrast agent).

# Therapeutics:

8



- More efficient uptake of drugs using existing drugs which are reformulated as nanocrystals or encapsulated.
- Tissue-specific delivery with a strong localized dose-control a lower overall concentration of the drug, providing lower patient toxicity and side-effects.
- Triggered drug release by a secondary mechanism such as light, pH, heat or enzyme activation.
- Diagnose and treat neurodegenerative disease with particles having the ability to cross the BBB.
- Therapeutic treatment with heat (magn. hyperthermia) light (QD)



# Nanoparticles

Nanoparticle (NP)	Properties of NP	Applications
Semiconductor NP	<p>Electron-hole pair</p> <p>Surface plasmon resonance</p>	<p>White light imaging   In vivo imaging</p>
Metal NP	<p>Surface plasmon resonance</p>	<p>Targeted Au NPs   Non-targeted Au NPs</p> <p>SPS Intensity (a.u.)   Raman shift (cm<sup>-1</sup>)</p> <p>0 400 800 1,200 1,600 2,000</p> <p>0 400 800 1,200 1,600 2,000</p> <p>Increase in PA amplitude (%)</p> <p>0 10 20 30 40 50</p> <p>Z (mm)</p> <p>0 10 20 30 40 50</p> <p>PEG-NPs + Laser   Saline + Laser</p>
Metal oxide NP	<p>Magnetic resonance</p>	<p>Pre-injection   Post-injection</p> <p>Core shell nanoparticles</p> <p>Untreated control</p> <p>Pre-treatment   Post-treatment</p>
Lanthanide-doped NP	<p>Upconversion</p> <p>Magnetic Resonance</p>	<p>La NP</p> <p>Unlabeled cells - dGEMC</p> <p>Pre-injection   Post-injection</p> <p>High   Low</p> <p>T<sub>1</sub>-weighted image</p> <p>Gd<sup>3+</sup> (mM) 0.00 0.06 0.6</p> <p>T<sub>1</sub> (ms) 1558 1008 707</p>

Nam et al.  
Advanced Drug Delivery Reviews 65  
(2013) 622–648



# Core and Surface properties


10

## Nanoeffects

- Ferro- to superparamagnetism
- Band gap change (fluorescence)
- Surface plasmon




## Scaling effects

- Increased reactivity per mass
- Solubility
- Colloidal stability
- Penetration through barriers



# Nanoeffects

11




# Outline

12

- Overview
- Why inorganic Nanoparticles for medical applications?
  - Needs from the medical side
  - Potential from the material side
- **Examples:**
  - **Silica**
  - **QD**
  - **SPION**
- Interaction of nanoparticles with tissue, cells, proteins

# Mesoporous silica nanoparticles






# SILICA nanoparticles: trend

14

- The *in vivo* studies using MSNs have to date mainly focused on the delivery of the approved cancer drug Doxorubicin using folate as the targeting ligand.
- This should be extended to include novel cancer drugs under development, in clinical trials or excluded from the market due to severe side effects.
- Generating a particle platform where the ligands and drugs are easily replaced in accordance with the patient profile could constitute a true advantage for personalized medicine.

After Mamaeva et al. *Advanced Drug Delivery Reviews* 65 (2013) 689–702

# Superparamagnetic Iron oxide nanoparticle



# Quantum Dots

